{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T03:01:30Z","timestamp":1721012490971},"reference-count":10,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,17]]},"DOI":"10.7759\/cureus.15076","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T18:31:26Z","timestamp":1621276286000},"source":"Crossref","is-referenced-by-count":2,"title":["Osimertinib and Ramucirumab Induced Pyogenic Granulomas: A Possible Synergistic Effect of Dual Oncologic Therapy"],"prefix":"10.7759","author":[{"given":"Robert P","family":"Daze","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jewell","family":"Dinkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew H","family":"Mahoney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2017.4120","article-title":"Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine","volume":"154","author":"Cubir\u00f3 X","year":"2018","unstructured":"Cubir\u00f3 X, Planas-Ciudad S, Garcia-Muret MP, Puig L. Topical timolol for paronychia and pseudopyogenic granuloma in patients treated with epidermal growth factor receptor inhibitors and capecitabine. JAMA Dermatol. 2018, 154:99-100. 10.1001\/jamadermatol.2017.4120","journal-title":"JAMA Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.4103\/idoj.IDOJ_133_18","article-title":"Systemic drug-induced chronic paronychia and periungual pyogenic granuloma","volume":"9","author":"Wollina U","year":"2018","unstructured":"Wollina U. Systemic drug-induced chronic paronychia and periungual pyogenic granuloma. Indian Dermatol Online J. 2018, 9:293-8. 10.4103\/idoj.IDOJ_133_18","journal-title":"Indian Dermatol Online J"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.1925","article-title":"Somatic p.T771R KDR (VEGFR2) mutation arising in a sporadic angioma during ramucirumab therapy","volume":"151","author":"Lim YH","year":"2015","unstructured":"Lim YH, Odell ID, Ko CJ, Choate KA. Somatic p.T771R KDR (VEGFR2) mutation arising in a sporadic angioma during ramucirumab therapy. JAMA Dermatol. 2015, 151:1240-3. 10.1001\/jamadermatol.2015.1925","journal-title":"JAMA Dermatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231464","article-title":"Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment","volume":"12","author":"Ibe T","year":"2019","unstructured":"Ibe T, Hamamoto Y, Takabatake M, Kamoshida S. Development of pyogenic granuloma with strong vascular endothelial growth factor receptor-2 expression during ramucirumab treatment. BMJ Case Rep. 2019, 12:e231464. 10.1136\/bcr-2019-231464","journal-title":"BMJ Case Rep"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/351210","article-title":"Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management","volume":"2012","author":"Abdullah SE","year":"2012","unstructured":"Abdullah SE, Haigentz M Jr, Piperdi B. Dermatologic toxicities from monoclonal antibodies and tyrosine kinase inhibitors against EGFR: pathophysiology and management. Chemother Res Pract. 2012, 2012:351210. 10.1155\/2012\/351210","journal-title":"Chemother Res Pract"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04791.x","article-title":"Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors","volume":"50","author":"Balagula Y","year":"2011","unstructured":"Balagula Y, Garbe C, Myskowski PL, Hauschild A, Rapoport BL, Boers-Doets CB, Lacouture ME. Clinical presentation and management of dermatological toxicities of epidermal growth factor receptor inhibitors. Int J Dermatol. 2011, 50:129-46. 10.1111\/j.1365-4632.2010.04791.x","journal-title":"Int J Dermatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-2869","article-title":"Ramucirumab-induced multiple haemangiomas of the skin: two case reports","volume":"98","author":"Kosumi H","year":"2018","unstructured":"Kosumi H, Nishie W, Sugai T, et al.. Ramucirumab-induced multiple haemangiomas of the skin: two case reports. Acta Derm Venereol. 2018, 98:454-5. 10.2340\/00015555-2869","journal-title":"Acta Derm Venereol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1550","article-title":"Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2","volume":"13","author":"Ton NC","year":"2007","unstructured":"Ton NC, Parker GJ, Jackson A, et al.. Phase I evaluation of CDP791, a PEGylated di-Fab' conjugate that binds vascular endothelial growth factor receptor 2. Clin Cancer Res. 2007, 13:7113-8. 10.1158\/1078-0432.CCR-07-1550","journal-title":"Clin Cancer Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2017.1410287","article-title":"Eruptive cherry angiomas developing in a patient treated with ramucirumab","volume":"57","author":"Espinosa Lara P","year":"2018","unstructured":"Espinosa Lara P, Medina-Puente C, Riquelme Oliveira A, Jim\u00e9nez-Reyes J. Eruptive cherry angiomas developing in a patient treated with ramucirumab. Acta Oncol. 2018, 57:709-11. 10.1080\/0284186X.2017.1410287","journal-title":"Acta Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14693","article-title":"Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab","volume":"46","author":"Watanabe R","year":"2019","unstructured":"Watanabe R, Nakano E, Kawazoe A, et al.. Four cases of paradoxical cephalocervical pyogenic granuloma during treatment with paclitaxel and ramucirumab. J Dermatol. 2019, 46:e178-80. 10.1111\/1346-8138.14693","journal-title":"J Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/59328-osimertinib-and-ramucirumab-induced-pyogenic-granulomas-a-possible-synergistic-effect-of-dual-oncologic-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:26:59Z","timestamp":1707506819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/59328-osimertinib-and-ramucirumab-induced-pyogenic-granulomas-a-possible-synergistic-effect-of-dual-oncologic-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":10,"URL":"https:\/\/doi.org\/10.7759\/cureus.15076","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}